Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability
Background Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor. Objective To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-ye...
Gespeichert in:
Veröffentlicht in: | Multiple sclerosis journal - experimental, translational and clinical translational and clinical, 2021-04, Vol.7 (2), p.20552173211015503-20552173211015503 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 20552173211015503 |
---|---|
container_issue | 2 |
container_start_page | 20552173211015503 |
container_title | Multiple sclerosis journal - experimental, translational and clinical |
container_volume | 7 |
creator | Sotiropoulos, Marinos G Lokhande, Hrishikesh Healy, Brian C Polgar-Turcsanyi, Mariann Glanz, Bonnie I Bakshi, Rohit Weiner, Howard L Chitnis, Tanuja |
description | Background
Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor.
Objective
To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes.
Methods
Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes.
Results
Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking.
Conclusions
Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability. |
doi_str_mv | 10.1177/20552173211015503 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8165535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_20552173211015503</sage_id><sourcerecordid>2539524042</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-3f0e44c53a7fda8cc90bfdc6ae687d4edffe5e5ee551a0555bc1ecde388709223</originalsourceid><addsrcrecordid>eNp1kV1LHTEQhkNpqWL9Ad6UQG96szafmz29KBSxHyAIotchm8weI9nkNMkK5983h2PVtkguEt555p2ZDEInlJxSqtQnRqRkVHFGKaFSEv4KHe60bie-fvY-QMel3BHSqL6J9C064IISIRQ9RO4KgtkUwBlsuoe8xT7ieQnVbwLgYgPkVHz5jM-nCWzFacI1g6kzxIpNdNimWLMfl-pTxDXhkOK6q5Bn7Hwxow--bt-hN5MJBY4f7iN08-38-uxHd3H5_efZ14vOir6vHZ8ICGElN2pyZrB2RcbJ2d5APygnwLUWZDsgJTVtOjlaCtYBHwZFVozxI_Rl77tZxhmcbT1mE_Qm-9nkrU7G678j0d_qdbrXA-2l5LIZfHwwyOnXAqXq2RcLIZgIaSmaSb6STBCxq_XhH_QuLTm28RollBCMqaFRdE_Z9o0lw_TYDCV6t0b93xpbzvvnUzxm_FlaA073QDFreCr7suNvGRynOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2547442278</pqid></control><display><type>article</type><title>Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability</title><source>PMC (PubMed Central)</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sotiropoulos, Marinos G ; Lokhande, Hrishikesh ; Healy, Brian C ; Polgar-Turcsanyi, Mariann ; Glanz, Bonnie I ; Bakshi, Rohit ; Weiner, Howard L ; Chitnis, Tanuja</creator><creatorcontrib>Sotiropoulos, Marinos G ; Lokhande, Hrishikesh ; Healy, Brian C ; Polgar-Turcsanyi, Mariann ; Glanz, Bonnie I ; Bakshi, Rohit ; Weiner, Howard L ; Chitnis, Tanuja</creatorcontrib><description>Background
Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor.
Objective
To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes.
Methods
Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes.
Results
Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking.
Conclusions
Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.</description><identifier>ISSN: 2055-2173</identifier><identifier>EISSN: 2055-2173</identifier><identifier>DOI: 10.1177/20552173211015503</identifier><identifier>PMID: 34104471</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Cohort analysis ; Disability ; Medical prognosis ; Multiple sclerosis ; Original Research Paper</subject><ispartof>Multiple sclerosis journal - experimental, translational and clinical, 2021-04, Vol.7 (2), p.20552173211015503-20552173211015503</ispartof><rights>The Author(s) 2021</rights><rights>The Author(s) 2021.</rights><rights>The Author(s) 2021. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021 2021 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-3f0e44c53a7fda8cc90bfdc6ae687d4edffe5e5ee551a0555bc1ecde388709223</citedby><cites>FETCH-LOGICAL-c466t-3f0e44c53a7fda8cc90bfdc6ae687d4edffe5e5ee551a0555bc1ecde388709223</cites><orcidid>0000-0002-3032-7069 ; 0000-0001-5272-2425 ; 0000-0001-8601-5534 ; 0000-0002-9897-4422</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165535/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165535/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34104471$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sotiropoulos, Marinos G</creatorcontrib><creatorcontrib>Lokhande, Hrishikesh</creatorcontrib><creatorcontrib>Healy, Brian C</creatorcontrib><creatorcontrib>Polgar-Turcsanyi, Mariann</creatorcontrib><creatorcontrib>Glanz, Bonnie I</creatorcontrib><creatorcontrib>Bakshi, Rohit</creatorcontrib><creatorcontrib>Weiner, Howard L</creatorcontrib><creatorcontrib>Chitnis, Tanuja</creatorcontrib><title>Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability</title><title>Multiple sclerosis journal - experimental, translational and clinical</title><addtitle>Mult Scler J Exp Transl Clin</addtitle><description>Background
Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor.
Objective
To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes.
Methods
Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes.
Results
Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking.
Conclusions
Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.</description><subject>Cohort analysis</subject><subject>Disability</subject><subject>Medical prognosis</subject><subject>Multiple sclerosis</subject><subject>Original Research Paper</subject><issn>2055-2173</issn><issn>2055-2173</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kV1LHTEQhkNpqWL9Ad6UQG96szafmz29KBSxHyAIotchm8weI9nkNMkK5983h2PVtkguEt555p2ZDEInlJxSqtQnRqRkVHFGKaFSEv4KHe60bie-fvY-QMel3BHSqL6J9C064IISIRQ9RO4KgtkUwBlsuoe8xT7ieQnVbwLgYgPkVHz5jM-nCWzFacI1g6kzxIpNdNimWLMfl-pTxDXhkOK6q5Bn7Hwxow--bt-hN5MJBY4f7iN08-38-uxHd3H5_efZ14vOir6vHZ8ICGElN2pyZrB2RcbJ2d5APygnwLUWZDsgJTVtOjlaCtYBHwZFVozxI_Rl77tZxhmcbT1mE_Qm-9nkrU7G678j0d_qdbrXA-2l5LIZfHwwyOnXAqXq2RcLIZgIaSmaSb6STBCxq_XhH_QuLTm28RollBCMqaFRdE_Z9o0lw_TYDCV6t0b93xpbzvvnUzxm_FlaA073QDFreCr7suNvGRynOA</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Sotiropoulos, Marinos G</creator><creator>Lokhande, Hrishikesh</creator><creator>Healy, Brian C</creator><creator>Polgar-Turcsanyi, Mariann</creator><creator>Glanz, Bonnie I</creator><creator>Bakshi, Rohit</creator><creator>Weiner, Howard L</creator><creator>Chitnis, Tanuja</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3032-7069</orcidid><orcidid>https://orcid.org/0000-0001-5272-2425</orcidid><orcidid>https://orcid.org/0000-0001-8601-5534</orcidid><orcidid>https://orcid.org/0000-0002-9897-4422</orcidid></search><sort><creationdate>20210401</creationdate><title>Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability</title><author>Sotiropoulos, Marinos G ; Lokhande, Hrishikesh ; Healy, Brian C ; Polgar-Turcsanyi, Mariann ; Glanz, Bonnie I ; Bakshi, Rohit ; Weiner, Howard L ; Chitnis, Tanuja</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-3f0e44c53a7fda8cc90bfdc6ae687d4edffe5e5ee551a0555bc1ecde388709223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cohort analysis</topic><topic>Disability</topic><topic>Medical prognosis</topic><topic>Multiple sclerosis</topic><topic>Original Research Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sotiropoulos, Marinos G</creatorcontrib><creatorcontrib>Lokhande, Hrishikesh</creatorcontrib><creatorcontrib>Healy, Brian C</creatorcontrib><creatorcontrib>Polgar-Turcsanyi, Mariann</creatorcontrib><creatorcontrib>Glanz, Bonnie I</creatorcontrib><creatorcontrib>Bakshi, Rohit</creatorcontrib><creatorcontrib>Weiner, Howard L</creatorcontrib><creatorcontrib>Chitnis, Tanuja</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Multiple sclerosis journal - experimental, translational and clinical</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sotiropoulos, Marinos G</au><au>Lokhande, Hrishikesh</au><au>Healy, Brian C</au><au>Polgar-Turcsanyi, Mariann</au><au>Glanz, Bonnie I</au><au>Bakshi, Rohit</au><au>Weiner, Howard L</au><au>Chitnis, Tanuja</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability</atitle><jtitle>Multiple sclerosis journal - experimental, translational and clinical</jtitle><addtitle>Mult Scler J Exp Transl Clin</addtitle><date>2021-04-01</date><risdate>2021</risdate><volume>7</volume><issue>2</issue><spage>20552173211015503</spage><epage>20552173211015503</epage><pages>20552173211015503-20552173211015503</pages><issn>2055-2173</issn><eissn>2055-2173</eissn><abstract>Background
Although recovery from relapses in MS appears to contribute to disability, it has largely been ignored as a treatment endpoint and disability predictor.
Objective
To identify demographic and clinical predictors of relapse recovery in the first 3 years and examine its contribution to 10-year disability and MRI outcomes.
Methods
Relapse recovery was retrospectively assessed in 360 patients with MS using the return of the Expanded Disability Status Scale (EDSS), Functional System Scale and neurologic signs to baseline at least 6 months after onset. Univariate and multivariable models were used to associate recovery with demographic and clinical factors and predict 10-year outcomes.
Results
Recovery from relapses in the first 3 years was better in patients who were younger, on disease-modifying treatment, with a longer disease duration and without bowel or bladder symptoms. For every incomplete recovery, 10-year EDSS increased by 0.6 and 10-year timed 25-foot walk increased by 0.5 s. These outcomes were also higher with older age and higher baseline BMI. Ten-year MRI brain atrophy was associated only with older age, and MRI lesion volume was only associated with smoking.
Conclusions
Early initiation of disease-modifying treatment in MS was associated with improved relapse recovery, which in turn prevented long-term disability.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>34104471</pmid><doi>10.1177/20552173211015503</doi><orcidid>https://orcid.org/0000-0002-3032-7069</orcidid><orcidid>https://orcid.org/0000-0001-5272-2425</orcidid><orcidid>https://orcid.org/0000-0001-8601-5534</orcidid><orcidid>https://orcid.org/0000-0002-9897-4422</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2055-2173 |
ispartof | Multiple sclerosis journal - experimental, translational and clinical, 2021-04, Vol.7 (2), p.20552173211015503-20552173211015503 |
issn | 2055-2173 2055-2173 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8165535 |
source | PMC (PubMed Central); DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Cohort analysis Disability Medical prognosis Multiple sclerosis Original Research Paper |
title | Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T07%3A37%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relapse%20recovery%20in%20multiple%20sclerosis:%20Effect%20of%20treatment%20and%20contribution%20to%20long-term%20disability&rft.jtitle=Multiple%20sclerosis%20journal%20-%20experimental,%20translational%20and%20clinical&rft.au=Sotiropoulos,%20Marinos%20G&rft.date=2021-04-01&rft.volume=7&rft.issue=2&rft.spage=20552173211015503&rft.epage=20552173211015503&rft.pages=20552173211015503-20552173211015503&rft.issn=2055-2173&rft.eissn=2055-2173&rft_id=info:doi/10.1177/20552173211015503&rft_dat=%3Cproquest_pubme%3E2539524042%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2547442278&rft_id=info:pmid/34104471&rft_sage_id=10.1177_20552173211015503&rfr_iscdi=true |